The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Clears major obesity endpoints at 80 weeks
AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
